eTheRNA Completes Enrolment of Low Dose Cohort for Phase 1b Study of TriMix mRNA-based Cancer Specific Immunotherapy (ECI-006) in Melanoma

March 18, 2018

Responsive image

NIEL, Belgium, March 19, 2018 /PRNewswire/ —
ECI-006 is safe and well tolerated
eTheRNA immunotherapies, a clinical-stage company developing novel cancer immunotherapies based on its unique mRNA-based TriMix platform, announces that it has completed enrolment of the low dose…

Category: Precious Metals